Covidien Submits Label Change for Optimark Contrast Agent

Covidien Plc stated that it will voluntarily contraindicate the use of its Optimark gadoversetamide injection, a gadolinium-based contrast agent or GBCA, in magnetic resonance imaging or MRI procedures involving patients with severe renal impairment.
RTTNews